480 related articles for article (PubMed ID: 25936305)
21. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
Kassner U; Schlabs T; Rosada A; Steinhagen-Thiessen E
Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335
[TBL] [Abstract][Full Text] [Related]
22. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
[TBL] [Abstract][Full Text] [Related]
23. Different apoprotein(a) isoform proportions in serum and carotid plaque.
Baldo G; Giunco S; Kontothanassis D; Baiocchi MR; Valerio A; Frego M
Atherosclerosis; 2007 Jul; 193(1):177-85. PubMed ID: 16839560
[TBL] [Abstract][Full Text] [Related]
24. Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.
Kimak E; Solski J
Ren Fail; 2002 Mar; 24(2):187-95. PubMed ID: 12071592
[TBL] [Abstract][Full Text] [Related]
25. Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure.
Sechi LA; Zingaro L; Catena C; Perin A; De Marchi S; Bartoli E
Kidney Int; 1999 Sep; 56(3):1049-57. PubMed ID: 10469373
[TBL] [Abstract][Full Text] [Related]
26. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes.
Pan J; Van JT; Chan E; Kesala RL; Lin M; Charles MA
Metabolism; 2002 Sep; 51(9):1120-7. PubMed ID: 12200755
[TBL] [Abstract][Full Text] [Related]
27. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
Vogt A
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
[TBL] [Abstract][Full Text] [Related]
28. Hyperhomocysteinemia and hyperlipoproteinemia (a) in obese South Indian men: an indication for increased cardiovascular risk.
Ikkruthi S; Rajappa M; Nandeesha H; Satheesh S; Sundar I; Ananthanarayanan PH; Harichandrakumar KT
Acta Physiol Hung; 2014 Mar; 101(1):13-20. PubMed ID: 24311227
[TBL] [Abstract][Full Text] [Related]
29. Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting.
Ezhov MV; Safarova MS; Afanasieva OI; Kukharchuk VV; Pokrovsky SN
Atherosclerosis; 2014 Aug; 235(2):477-82. PubMed ID: 24952151
[TBL] [Abstract][Full Text] [Related]
30. Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.
Koschinsky ML
Curr Atheroscler Rep; 2005 Sep; 7(5):389-95. PubMed ID: 16105483
[TBL] [Abstract][Full Text] [Related]
31. Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk.
Yeang C; Clopton PC; Tsimikas S
J Clin Lipidol; 2016; 10(6):1389-1396. PubMed ID: 27919356
[TBL] [Abstract][Full Text] [Related]
32. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production.
Rader DJ; Cain W; Zech LA; Usher D; Brewer HB
J Clin Invest; 1993 Feb; 91(2):443-7. PubMed ID: 8432853
[TBL] [Abstract][Full Text] [Related]
33. [Not Available].
Tmoyan NA; Afanasieva OI; Klesareva EA; Afanasieva MI; Razova OA; Ezhov MV; Pokrovsky SN
Kardiologiia; 2018 Dec; 58(12):45-51. PubMed ID: 30625096
[TBL] [Abstract][Full Text] [Related]
34. Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease.
Dieplinger B; Lingenhel A; Baumgartner N; Poelz W; Dieplinger H; Haltmayer M; Kronenberg F; Mueller T
Clin Chem; 2007 Jul; 53(7):1298-305. PubMed ID: 17525104
[TBL] [Abstract][Full Text] [Related]
35. The association of lipoprotein(a) and apolipoprotein(a) phenotypes with peripheral artery disease.
Tmoyan NA; Ezhov MV; Afanasieva OI; Klesareva EA; Razova OA; Kukharchuk VV; Pokrovsky SN
Ter Arkh; 2018 Sep; 90(9):31-36. PubMed ID: 30701732
[TBL] [Abstract][Full Text] [Related]
36. Decrease of Lp(a) during weight reduction in obese children is modified by the apo(a) kringle-IV copy number variation.
Brandstätter A; Lingenhel A; Zwiauer K; Strobl W; Kronenberg F
Int J Obes (Lond); 2009 Oct; 33(10):1136-42. PubMed ID: 19636317
[TBL] [Abstract][Full Text] [Related]
37. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure.
Milionis HJ; Elisaf MS; Tselepis A; Bairaktari E; Karabina SA; Siamopoulos KC
Am J Kidney Dis; 1999 Jun; 33(6):1100-6. PubMed ID: 10352198
[TBL] [Abstract][Full Text] [Related]
38. Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients.
Croyal M; Ouguerram K; Passard M; Ferchaud-Roucher V; Chétiveaux M; Billon-Crossouard S; de Gouville AC; Lambert G; Krempf M; Nobécourt E
Arterioscler Thromb Vasc Biol; 2015 Sep; 35(9):2042-7. PubMed ID: 26160958
[TBL] [Abstract][Full Text] [Related]
39. Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.
Chan DC; Watts GF; Coll B; Wasserman SM; Marcovina SM; Barrett PHR
J Am Heart Assoc; 2019 Apr; 8(7):e011781. PubMed ID: 30897995
[TBL] [Abstract][Full Text] [Related]
40. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure.
Kronenberg F; Kuen E; Ritz E; Junker R; König P; Kraatz G; Lhotta K; Mann JFE; Müller GA; Neyer U; Riegel W; Riegler P; Schwenger V; VON Eckardstein A
J Am Soc Nephrol; 2000 Jan; 11(1):105-115. PubMed ID: 10616846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
